Your browser doesn't support javascript.
loading
Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.
Gotink, Annieke W; van de Ven, Steffi E M; Ten Kate, Fiebo J C; Nieboer, Daan; Suzuki, Lucia; Weusten, Bas L A M; Brosens, Lodewijk A A; van Hillegersberg, Richard; Alvarez Herrero, Lorenza; Seldenrijk, Cees A; Alkhalaf, Alaa; Moll, Freek C P; Schoon, Erik J; van Lijnschoten, Ineke; Tang, Thjon J; van der Valk, Hans; Nagengast, Wouter B; Kats-Ugurlu, Gursah; Plukker, John T M; Houben, Martin H M G; van der Laan, Jaap S; Pouw, Roos E; Bergman, Jacques J G H M; Meijer, Sybren L; van Berge Henegouwen, Mark I; Wijnhoven, Bas P L; de Jonge, Pieter Jan F; Doukas, Michael; Bruno, Marco J; Biermann, Katharina; Koch, Arjun D.
Afiliação
  • Gotink AW; Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • van de Ven SEM; Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Ten Kate FJC; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Nieboer D; Department of Pathology, Isala Clinics, Zwolle, the Netherlands.
  • Suzuki L; Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Weusten BLAM; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Brosens LAA; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • van Hillegersberg R; Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Alvarez Herrero L; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Seldenrijk CA; Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Alkhalaf A; Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Moll FCP; Department of Pathology, Pathology DNA, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Schoon EJ; Department of Gastroenterology and Hepatology, Isala Clinics, Zwolle, the Netherlands.
  • van Lijnschoten I; Department of Pathology, Isala Clinics, Zwolle, the Netherlands.
  • Tang TJ; Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, the Netherlands.
  • van der Valk H; Department of Pathology, PAMM, Eindhoven, the Netherlands.
  • Nagengast WB; Department of Gastroenterology and Hepatology, Ijsselland Hospital, Capelle aan den Ijssel, the Netherlands.
  • Kats-Ugurlu G; Department of Pathology, Ijselland Hospital, Capelle aan den Ijssel, the Netherlands.
  • Plukker JTM; Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, the Netherlands.
  • Houben MHMG; Department of Pathology, University Medical Center Groningen, Groningen, the Netherlands.
  • van der Laan JS; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
  • Pouw RE; Department of Gastroenterology and Hepatology, Haga Teaching Hospital, Den Haag, the Netherlands.
  • Bergman JJGHM; Department of Pathology, Haga Teaching Hospital, Den Haag, the Netherlands.
  • Meijer SL; Department of Gastroenterology and Hepatology, Cancer Center Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • van Berge Henegouwen MI; Department of Gastroenterology and Hepatology, Cancer Center Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Wijnhoven BPL; Department of Pathology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • de Jonge PJF; Department of Surgery, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Doukas M; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Bruno MJ; Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Biermann K; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Koch AD; Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Endoscopy ; 54(2): 109-117, 2022 02.
Article em En | MEDLINE | ID: mdl-33626582
ABSTRACT

BACKGROUND:

Lymph node metastasis (LNM) is possible after endoscopic resection of early esophageal adenocarcinoma (EAC). This study aimed to develop and internally validate a prediction model that estimates the individual risk of metastases in patients with pT1b EAC.

METHODS:

A nationwide, retrospective, multicenter cohort study was conducted in patients with pT1b EAC treated with endoscopic resection and/or surgery between 1989 and 2016. The primary end point was presence of LNM in surgical resection specimens or detection of metastases during follow-up. All resection specimens were histologically reassessed by specialist gastrointestinal pathologists. Subdistribution hazard regression analysis was used to develop the prediction model. The discriminative ability of this model was assessed using the c-statistic.

RESULTS:

248 patients with pT1b EAC were included. Metastases were seen in 78 patients, and the 5-year cumulative incidence was 30.9 % (95 % confidence interval [CI] 25.1 %-36.8 %). The risk of metastases increased with submucosal invasion depth (subdistribution hazard ratio [SHR] 1.08, 95 %CI 1.02-1.14, for every increase of 500 µm), lymphovascular invasion (SHR 2.95, 95 %CI 1.95-4.45), and for larger tumors (SHR 1.23, 95 %CI 1.10-1.37, for every increase of 10 mm). The model demonstrated good discriminative ability (c-statistic 0.81, 95 %CI 0.75-0.86).

CONCLUSIONS:

A third of patients with pT1b EAC experienced metastases within 5 years. The probability of developing post-resection metastases was estimated with a personalized predicted risk score incorporating tumor invasion depth, tumor size, and lymphovascular invasion. This model requires external validation before implementation into clinical practice.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Endoscopy Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Endoscopy Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda